semaglutide provider near me — Provider-Supervised GLP-1 Program Ozempic Weight Loss Injections &

GLP-1s role as an insulinotropic incretin remained undetermined until GLP-1 (7-37), a truncated form of GLP-1, was identified by Mojsov et al

Background Semaglutide is the active ingredient in Ozempic and Wegovy, developed by Novo Nordisk A/S

In the landmark study that introduced it, published in Cell Metabolism (Lee et al., 2015), researchers showed that MOTS-c regulates insulin sensitivity and metabolic homeostasis through the AMPK pathway, and that treatment prevented diet-induced obesity and insulin resistance in animal models

Lack of Clinical Evidence Critical gaps in knowledge: Zero randomized controlled trials on microdosing GLP-1 agonists No long-term safety data for alternative dosing regimens Unknown effects on cardiovascular outcomes Potential for reduced efficacy not captured in models 3